Justin Kim
Stock Analyst at Oppenheimer
(1.51)
# 3,475
Out of 5,044 analysts
37
Total ratings
41.38%
Success rate
-7.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Outperform | $17 → $16 | $3.77 | +324.40% | 2 | Aug 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $65 → $40 | $30.05 | +33.11% | 6 | Nov 6, 2024 | |
| PHVS Pharvaris | Maintains: Outperform | $38 → $42 | $22.65 | +85.43% | 4 | Sep 6, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $107 → $106 | $61.97 | +71.05% | 5 | May 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $85 → $87 | $33.75 | +157.78% | 5 | Feb 29, 2024 | |
| VERA Vera Therapeutics | Initiates: Outperform | $26 | $29.96 | -13.22% | 1 | Jan 25, 2024 | |
| ALDX Aldeyra Therapeutics | Downgrades: Perform | n/a | $5.14 | - | 2 | Oct 17, 2023 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Perform | n/a | $12.63 | - | 6 | Nov 4, 2022 | |
| BCRX BioCryst Pharmaceuticals | Downgrades: Perform | n/a | $7.24 | - | 5 | Aug 8, 2022 | |
| IONS Ionis Pharmaceuticals | Assumes: Outperform | $59 | $73.57 | -19.80% | 1 | Jul 18, 2022 |
Zura Bio
Aug 15, 2025
Maintains: Outperform
Price Target: $17 → $16
Current: $3.77
Upside: +324.40%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $65 → $40
Current: $30.05
Upside: +33.11%
Pharvaris
Sep 6, 2024
Maintains: Outperform
Price Target: $38 → $42
Current: $22.65
Upside: +85.43%
Cytokinetics
May 9, 2024
Maintains: Outperform
Price Target: $107 → $106
Current: $61.97
Upside: +71.05%
Immunocore Holdings
Feb 29, 2024
Reiterates: Outperform
Price Target: $85 → $87
Current: $33.75
Upside: +157.78%
Vera Therapeutics
Jan 25, 2024
Initiates: Outperform
Price Target: $26
Current: $29.96
Upside: -13.22%
Aldeyra Therapeutics
Oct 17, 2023
Downgrades: Perform
Price Target: n/a
Current: $5.14
Upside: -
Aurinia Pharmaceuticals
Nov 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $12.63
Upside: -
BioCryst Pharmaceuticals
Aug 8, 2022
Downgrades: Perform
Price Target: n/a
Current: $7.24
Upside: -
Ionis Pharmaceuticals
Jul 18, 2022
Assumes: Outperform
Price Target: $59
Current: $73.57
Upside: -19.80%